The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) — a tool commonly used to determine disease activity in systemic lupus erythematosus patients — misses nearly two of out three patients with clinically meaningful changes in disease activity, a Portuguese study found. The study, “Performance of SLEDAI-2K…
News
The immunosuppressive agent tacrolimus, used in combination with other immunosuppressants, was deemed safe and effective for treatment of lupus nephritis, a serious complication of systemic lupus erythematosus (SLE), a new study shows. The study, “Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis,” was published…
APVO210, an antibody to treat autoimmune and inflammatory diseases such as lupus, has entered a Phase 1 clinical trial to test its safety and tolerability in healthy volunteers, announced its developer Aptevo Therapeutics. Conducted in Australia, the study (NCT03768219) is meant to determine APVO210’s optimal dose and regimen for…
The U.S. Patent and Trademark Office (USPTO) is issuing a new patent to Aurinia Pharmaceuticals covering a method of use and dosing protocol of the immunosuppressant voclosporin in patients with lupus nephritis. The patent (No. 15/835,219), titled “Protocol for Treatment of Lupus Nephritis” covers an individualized treatment protocol where…
Equillium announced that it is planning to test EQ001, its monoclonal antibody, in a Phase 1b trial as a potential therapy for patients with refractory lupus nephritis, among the most frequent and severe manifestations of lupus and one that can progress to kidney failure. “Our decision to explore EQ001 for…
Aiming to distill the latest in a record number of ongoing global research in lupus, the Lupus Foundation of America (LFA) has created a new digital resource called Inside Lupus Research. The dedicated online source for research updates is hosted on the Foundation’s website. Designed for patients…
Eliminating B-cells using a recent form of immunotherapy that employs genetically modified T-cells is able to treat lupus in mice in a stable and efficient way, a study funded by Lupus Research Alliance shows.
Dressed in signature purple attire or accessories, more than 350 lupus advocates from around the U.S. came together on Capitol Hill earlier this month to urge Congress to earmark more funds for lupus research and education. As part of the Lupus Foundation of America’s 2019 National Lupus Advocacy…
High blood pressure and a skin condition characterized by a netlike pattern of reddish-blue skin discoloration — livedo reticularis — may be risk factors for peripheral nervous system manifestations in systemic lupus erythematosus (SLE), a retrospective study suggests. The study, “Peripheral nervous system involvement in systemic…
The Lupus Research Alliance and its affiliate, Lupus Therapeutics, have partnered with Takeda Pharmaceutical to conduct a Phase 1 clinical trial testing Takeda’s investigational antibody TAK-079 for the treatment of systemic lupus erythematosus (SLE) patients. The trial (NCT03724916), which will include approximately 24 participants across the U.S., is for patients with…
Recent Posts
- Accepting help allows us to preserve our health and energy
- Experimental skin lupus therapy dropped after trial misses main goal
- When we’re too sick to work, but not sick enough for disability
- Embracing an earworm song can benefit those of us with lupus
- Alliance awards over $2M for lifestyle intervention studies in lupus